Drugs / COR588
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04920903 | Aug 2021 → Apr 2022 | — | Cortexyme Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COR588 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04920903 ↗ |
| Route | Oral | “Oral COR588” NCT04920903 ↗ |